Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 11 Aug 2021 for Nurix Therapeutics, Inc., €7,101. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Pierre Beaurang: trading record in brief
Pierre Beaurang, listed as senior executive, appears in our data through filings on Nurix Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 10 May 2021 to 10 August 2021, the count stands at 4 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 11 August 2021, the filings show an option exercise worth €7,101 in Nurix Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Pierre Beaurang
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
7,500 shares@ US$1.1125.5% of flowCommon StockSEC:0001209191-21-050976:0
7,500 shares@ US$1.1125.2% of flowCommon StockSEC:0001209191-21-046362:0
7,500 shares@ US$1.1124.6% of flowCommon StockSEC:0001209191-21-039810:0
7,500 shares@ US$1.1124.7% of flowCommon StockSEC:0001209191-21-031891:0
4 of 4 declarations
